Fat-soluble pyrrolidinone racetam nootropic with multi-target modulation of GABAergic, cholinergic, and glutamatergic neurotransmission
A lipophilic 2-oxopyrrolidinyl acetamide derived from the piracetam scaffold, developed by Daiichi Pharmaceutical as an antiamnesic agent for cerebrovascular dementia and distinguished from other racetams by concurrent modulation of GABA-A receptors, neuronal nicotinic acetylcholine receptors, voltage-gated calcium channels, and NMDA receptor function through convergent protein kinase C and CaM kinase II signaling.
Abstract
Nefiracetam (DM-9384, Translon), the N-(2,6-dimethylphenyl) acetamide derivative of 2-oxopyrrolidine and the most pharmacologically characterized fat-soluble member of the racetam nootropic class, is a cognition-enhancing agent developed by Daiichi Pharmaceutical (now Daiichi Sankyo) in Japan during the 1980s for the treatment of cognitive impairment secondary to cerebrovascular disease. Unlike the parent compound piracetam, which acts principally through membrane fluidity modulation and non-specific cholinergic facilitation, nefiracetam engages a convergent set of molecular targets: high-affinity interaction with the GABA-A receptor chloride channel complex (IC50 approximately 8.5 nM for displacement of [3H]muscimol binding), potentiation of neuronal nicotinic acetylcholine receptor currents through a G-protein-coupled protein kinase C pathway, enhancement of voltage-gated L-type and N-type calcium channel currents, potentiation of NMDA receptor function via protein kinase C activation with consequent reduction of the voltage-dependent magnesium block, and facilitation of hippocampal long-term potentiation through CaM kinase II and protein kinase C alpha activation downstream of NMDA receptor and metabotropic glutamate receptor 5 stimulation. The composite pharmacology produces a sustained facilitation of hippocampal synaptic transmission that resembles long-term potentiation and that depends on presynaptic nicotinic acetylcholine receptor activation and consequent glutamate release.
Less than 10 percent of the administered dose is excreted unchanged in urine. The compound crosses the blood-brain barrier readily owing to its lipophilicity relative to piracetam.
The clinical development program encompassed three principal indications. In cerebrovascular dementia, Phase 2 and Phase 3 trials conducted in Japan by Daiichi demonstrated cognitive improvement in patients with sequelae of cerebral infarction; however, a revised Phase 3 trial failed to meet its primary endpoint, and the New Drug Application was withdrawn in Japan in February 2002.
The compound is not approved in any jurisdiction as of the current monograph date. It is available as a research-grade preparation from multiple chemical suppliers. The principal preclinical toxicology concern is species-specific nephrotoxicity observed in dogs and rats attributable to a metabolite (M-18) that is not formed in humans or primates; long-term studies in humans and primates have not identified renal toxicity. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.